Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476916 · ClinicalTrials.gov registry record · Phase 2
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
A Phase 2 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT02476916 is a Phase 2 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT02476916, a Phase 2 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency.
Interventions
- DRUG AG-348
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-06-26 |
| Est. Completion | 2025-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476916
The ClinicalTrials.gov registry entry for NCT02476916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-348 is the first listed.
NCT02476916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476916 about?
NCT02476916 is a clinical study titled "A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency". Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency.
What is the current status of trial NCT02476916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2015-06-26. Estimated completion is 2025-04-02.
What interventions are being tested in trial NCT02476916?
The interventions under investigation include: AG-348 (DRUG).
Who is sponsoring clinical trial NCT02476916?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.